VLA.PA stock jumped 6.49% to €4.63 at the EURONEXT close on 18 Feb 2026. Trading volume surged to 1,369,918 shares, well above the average of 865,425, signalling stronger buyer interest. The move lifted VLA.PA above its 50-day average of €3.98. Investors cited pipeline progress and technical momentum as drivers for the gain.
VLA.PA stock: Market close and volume snapshot
Valneva SE (VLA.PA) closed at €4.63 on EURONEXT on 18 Feb 2026, up 6.49% on the session. The stock traded between €4.54 and €4.72 today. Volume hit 1,369,918 shares, a 1.83x relative volume versus the average. Year range stands at €2.25 to €5.415.
VLA.PA stock: Drivers behind the daily gain
The immediate driver was stronger buying on higher volume and technical breakouts. Momentum indicators show an RSI of 67.91, near overbought, and a MACD histogram of 0.08. Peer and benchmark screens flagged Valneva as a relative outperformer versus biotech peers today source. Markets are also sensitive to pipeline timing and upcoming corporate news.
VLA.PA stock: Financials and valuation view
Valneva reports an EPS of -0.65 and a trailing PE of -7.13. Market cap is €797,458,934 with 172,088,678 shares outstanding. Price-to-sales is 2.87 and price-to-book is 4.04. The company shows a current ratio of 2.27 and cash per share €0.99, giving some liquidity buffer. Net income remains negative, but FY2024 showed revenue growth of 10.32%.
VLA.PA stock: Technical read and Meyka AI grade
Technicals show a strong short-term trend. ADX reads 26.98 and the 50-day average is €3.98, above the 200-day average €3.66. Momentum and volume indicators point to continuation risk if buyers slow. Meyka AI rates VLA.PA with a score of 62.30 out of 100 — Grade B and suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
VLA.PA stock: Forecasts and price targets
Meyka AI’s forecast model projects a yearly price of €5.04, a quarterly target of €5.73, and a monthly figure of €3.86. Compared with the current €4.63, the model implies a +8.89% yearly upside and a +23.76% quarterly upside. A conservative analyst price target sits at €5.50, a base target at €6.00, and a downside scenario near €3.50 if clinical or commercial setbacks emerge. Forecasts are model-based projections and not guarantees.
VLA.PA stock: Risks and upcoming catalysts
Key risks include ongoing losses, thin free cash flow, and high payables turnover. Valneva carries a debt-to-equity of 1.06 and negative free cash flow per share of €-0.21. Near-term catalysts include the earnings release scheduled for 19 Mar 2026 and trial updates for VLA1553 and VLA15. Partnerships with Pfizer and Instituto Butantan remain strategic positives. For peer comparison and sector context see benchmark screens source.
Final Thoughts
VLA.PA stock closed the session higher at €4.63, powered by elevated volume and bullish technical signals. The company still posts negative EPS (-0.65) and carries valuation compression, but recent revenue growth and pipeline milestones support a measured recovery. Meyka AI’s forecast model projects a yearly price of €5.04, implying +8.89% from today’s close. Short-term traders may watch momentum and the 19 Mar 2026 earnings date. Long-term investors should weigh clinical risk, cash runway, and partnerships before adding exposure. For quick reference, see Valneva on Meyka’s platform for real-time updates and tools: Valneva on Meyka. Forecasts are model-based projections and not guarantees.
FAQs
Why did VLA.PA stock rise today?
VLA.PA stock rose on higher-than-average volume and momentum. Technical indicators such as RSI and MACD signalled buyer strength. Market attention ahead of clinical updates and earnings also supported the move.
What is the Meyka price forecast for VLA.PA stock?
Meyka AI’s model shows a yearly projection of €5.04 for VLA.PA stock, implying +8.89% versus the current €4.63. These figures are model forecasts, not guarantees.
What risks should investors watch for VLA.PA stock?
Key risks include continued negative EPS, tight free cash flow, and operational payables. Clinical trial setbacks or weaker commercial uptake would pressure VLA.PA stock and the valuation.
When is Valneva’s next earnings and why it matters for VLA.PA stock?
Valneva reports earnings on 19 Mar 2026. The release may update revenue, cash flow, and pipeline timelines. Investors expect volatility in VLA.PA stock around that date.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)